Welcome to our dedicated page for Cannabix Technol news (Ticker: BLOZF), a resource for investors and traders seeking the latest updates and insights on Cannabix Technol stock.
Cannabix Technologies Inc. develops marijuana and alcohol breath-testing technologies for workplace safety, law enforcement, and other safety-sensitive settings. Company news centers on the Marijuana Breath Test, or MBT, including its Breath Collection Unit and single-use Breath Cartridges used to collect breath samples for laboratory analysis of recent cannabis use.
Recurring updates include commercial rollout activity, deliveries through authorized resellers, product validation, regulatory and compliance testing for device hardware, and distribution or education efforts with testing-industry partners. News also covers the company’s work with Omega Laboratories on analytical methods for detecting cannabinoids in breath samples using LC-MS-based testing.
Cannabix Technologies (OTC: BLOZF) announced its Marijuana Breath Test Breath Collection Unit (BCU) has secured UL 61010-1 (U.S.) and CSA 61010-1-12 (Canada) electrical safety certifications. Testing was completed at an ISO/IEC 17025 accredited lab, supporting commercialization of the MBT system in workplace, industrial, and law enforcement settings.
Cannabix Technologies (OTCID: BLOZF) delivered its Marijuana Breath Test (MBT) devices to a workplace drug and alcohol testing clinic serving eastern Canada on May 4, 2026. The delivery, completed via an authorized reseller, targets clinics seeking breath-based THC tools for recent-use assessment, non-invasive collection, and LC-MS lab confirmation.
The company positions MBT for post-incident, reasonable-cause, deterrence, and fitness-for-duty applications as clinics seek more timely, defensible testing than legacy urine or oral-fluid methods.
Cannabix Technologies (OTCID: BLOZF) announced that strategic partner Omega Laboratories will present the Cannabix Marijuana Breath Test (MBT) and host two educational panels at the NDASA Conference, April 26–29, 2026, in Orange County, California.
The MBT targets detection of delta-9 THC in breath within 4 hours of consumption and is designed for recent-use workplace screening.
Cannabix Technologies (OTCID: BLOZF) announced commercial delivery of its Marijuana Breath Test (MBT) to a Virginia industrial manufacturing client on April 1, 2026, completed via an authorized reseller.
The MBT detects delta-9 THC in breath within four hours above 5 pg/L, uses proprietary Breath Collection Unit and laboratory LC-MS analysis, and leverages a strategic partnership with Omega Laboratories.
Cannabix Technologies (OTCID: BLOZF) announced the first commercial delivery of its Marijuana Breath Test (MBT) to a major construction contractor on March 19, 2026. The MBT detects delta-9 THC in breath within approximately four hours at levels above 5 pg/L and uses single-use Breath Cartridges plus a Breath Collection Unit.
The company partners with Omega Laboratories for LC-MS laboratory analysis and plans to scale production through resellers targeting safety-sensitive sectors such as construction, transportation, and manufacturing.
Cannabix Technologies (OTCID: BLOZF) has commenced a phased commercial rollout of its Marijuana Breath Test (MBT) system, delivering units to select customers starting March 16, 2026. The MBT detects recent delta-9 THC in breath at >5 pg/L within ~4 hours of use and follows a recurring revenue model using disposable cartridges.
Key rollout enablers include a peer-reviewed Journal of Analytical Toxicology publication, partnership with Omega Laboratories for lab methods and LIMS integration, FCC emissions approval for the Breath Collection Unit, and established manufacturing, QA/QC, and training materials.
Omega Laboratories and Cannabix Technologies (OTCID: BLOZF) announced a peer‑reviewed validation published March 3, 2026 in the Journal of Analytical Toxicology confirming an LC‑MS/MS laboratory method to detect multiple cannabinoids in breath collected with the Cannabix Breath Collection Unit.
The study reports simultaneous quantification of Δ9‑THC, Δ8‑THC, CBD, and CBN, breath sample stability up to 7 days, and a detection window correlating with blood for recent use (about 15 minutes to 4 hours).
Cannabix Technologies (OTCID: BLOZF) announced its Marijuana Breath Test (MBT) will appear on the cover of AlcoPro 2026 product catalogue, which will be distributed to more than 85,000 businesses in the U.S. and internationally, including law enforcement and corrections.
Cannabix and AlcoPro are collaborating on pre-launch U.S. marketing for the MBT. The MBT combines Cannabix’s Breath Collection Unit and Breath Cartridge for non-invasive breath sampling intended for LC-MS analysis. Cannabix also highlights a strategic partnership with Omega Laboratories, a forensic drug-testing provider with over 25 years of certifications and experience.
Cannabix Technologies (OTCID: BLOZF) launched new product videos on Dec. 19, 2025 showcasing its Marijuana Breath Test (MBT) and related hardware, including the Breath Collection Unit (BCU) and Breath Cartridge (BC).
The videos describe the MBT’s non-invasive breath sampling to detect recent cannabis use and show integration with gold-standard LC-MS analysis and a strategic partnership with Omega Laboratories for commercialization in the U.S. and Canada.
The company links the MBT to growing demand following the U.S. Administration’s reclassification action and positions the device for workplace and roadside screening applications.
Cannabix Technologies (OTCID: BLOZF) announced that its handheld Breath Collection Unit (BCU) passed electronic emissions testing required by the US Federal Communications Commission (FCC) and Canada’s ISED standard ICES-003 Issue 7. Cannabix received an ISO/IEC 17025 accredited test report after testing at QAI Laboratories in British Columbia. The BCU and proprietary Breath Cartridges form the core of the Marijuana Breath Test (MBT) system, which aims to collect stable breath samples for analysis by LC-MS. Cannabix said this emissions clearance is a key regulatory milestone toward commercialization in the US and Canada.